Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/27548
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoongsangmanoon W.
dc.contributor.authorWattanawinitchai K.
dc.contributor.authorCharonpongsuntorn C.
dc.contributor.authorChonmaitree P.
dc.contributor.authorWongsoasup A.
dc.contributor.authorRattanajaruskul N.
dc.contributor.authorAngkananard T.
dc.date.accessioned2022-12-14T03:17:36Z-
dc.date.available2022-12-14T03:17:36Z-
dc.date.issued2022
dc.identifier.issn1252208
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85123318091&doi=10.35755%2fjmedassocthai.2022.S01.00030&partnerID=40&md5=0dc61225497cf3b9c8c93a9208cc471c
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/27548-
dc.description.abstractPazopanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. The authors describe a patient with advanced renal cell carcinoma who developed severe hypertension and severe left ventricular systolic dysfunction after starting pazopanib therapy with subsequent recovery of left ventricular ejection fraction upon treatment interruption. © JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
dc.languageen
dc.subjectbisoprolol
dc.subjectfurosemide
dc.subjecthydralazine
dc.subjectisosorbide dinitrate
dc.subjectlosartan
dc.subjectpazopanib
dc.subjectprotein tyrosine kinase inhibitor
dc.subjectsunitinib
dc.subjecttroponin
dc.subjectvalsartan
dc.subjectaged
dc.titlePazopanib-Induced Reversible Left Ventricular Systolic Dysfunction
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationJournal of the Medical Association of Thailand. Vol 105, No. (2022), p.S130-S133
dc.identifier.doi10.35755/jmedassocthai.2022.S01.00030
Appears in Collections:Scopus 2022

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.